Founded in 1988, WEGO works on developing medical devices and pharmaceuticals as its primary business, while expanding the architectural engineering, finance, and other areas. With more than 80 subsidiaries, 2 listed companies, and more than 30,000 employees, WEGO Holding Co., Ltd., which covers an area of more than 60 million square feet, consists of WEGO Group, WEGO Architecture Engineering Group, and WEGO Financial Holding Group. WEGO has 7 industry groups, including medical products, blood purification, orthopedics, medical equipment, pharmacy, intracardiac consumables, and medical business.

Main products of WEGO are infusion sets, syringes, blood transfusion equipment, intracardiac consumables, IV catheters, and special needles, blood purification equipment and consumables, orthopedic materials, operating equipment and accessories, trauma care, surgical robots, minimally invasive instruments and equipment, ICU products and accessories, high-capacity injections and other pharmaceuticals, renal products, biological diagnostic reagents, surgical sutures, dental implants, sense control equipment and consumables, PVC & non-PVC materials and so on. With more than 1000 varieties of products provided in more than 150,000 specifications, WEGO’s medical instruments now have entered into 11 fields out of 15 segmented markets, becoming one of the safest and reliable suppliers of medical system solutions in the world.

In order to further improve the innovation system, WEGO has established a national-recognized enterprise technology center, a national engineering laboratory of implants, a national innovation pilot enterprise, an academician workstation, a postdoctoral workstation, Shandong High-performance Medical Device Research Center, Shandong Medical Device Technology Innovation Center, a provincial engineering technology research center, Taishan Scholar Laboratory and other innovation platforms, accelerates the construction of three major platforms including WEGO Research Institute, National Innovation Center and Beijing & Changchun R & D Center, and carries out industry-university-research cooperation with more than 30 well-known universities and research institutes such as the Chinese Academy of Sciences, the Chinese Academy of Engineering, the Academy of Military Medical Sciences, Chinese PLA General Hospital, Harbin Industrial University and Tianjin University, with over 30 research institutions established.

WEGO has more than 1,100 patents, including more than 400 invention patents, possesses more than 900 products with independent intellectual property rights, among them, high-tech products and high value-added products account for more than 80%.  WEGO also has products such as orthopedic materials series, blood purification series, intracardiac consumables series, artificial liver, automatic chemiluminescence analyzer, color ultrasonic diagnosis, DR, prefilled syringes, membrane oxygenator, and protein A immunoadsorption column have broken foreign monopolies and become well-known international brands, etc.

Founded in 2004, Double Medical Technology Inc. (Ticker Symbol: SHE:002901) is one of the key high-tech enterprises and a large medical equipment group. With its six subsidies, Double Medical offers service, technology, and device in the area of orthopedics, wound management, neurosurgery, and general surgery. Double Medical′s orthopedic implants are a leader in the domestic market in China. Dedicated to rehabilitation, Double Medical focuses on providing high-quality, affordable products, quick logistics, and constant doctors’ support. The products are CE 0120 certified, approved by FDA 510(K), and Australian TGA.

Double Medical has branches in over 30 provinces and cities and is cooperating with more than 3,500 hospitals and nearly 1,000 business enterprises in China. Its products have been exported to more than 50 countries and regions that include EU, Russia, South  America, Australia, Southeast Asia, Middle East, and South Africa.

Established in 2005, Shanghai Kinetic Co., Ltd. has become a medical device manufacturer for multidisciplinary specialties, including Orthopedics, Cardiovascular, and Sports Medicine.

KMC was listed on the Growth Enterprises Market of Shenzhen Stock Exchange (3000326.SZ) in 2012, merged Beijing Essen and Jiangsu Ideal the second year.

While rapidly growing, KMC is also continually building up a creditworthy company image and creating strategic cooperation platforms at home and abroad by diversifying product lines, enhancing product quality, and completing service systems.

KMC keeps active communication with KOLs for consistent improvement and innovation to the products and medical solutions. It will always stick to the company’s original mission “to provide top quality products and the best value to the needs of the doctors and patients” simultaneously.

Chongqing Pharscin Pharmaceutical Co., Ltd. (“Pharscin Pharma”) is a large pharmaceutical company with the functions of R&D, manufacturing, and sales. The company focuses on both Chinese and Western medicines. On October 20, 2017, Pharscin Pharma launched its initial public offering of A-shares on Shenzhen Stock Exchange.(Stock code 002907). The company has 3 wholly-owned subsidiaries, namely Chongqing Pharscin Medicine Co., Ltd., Chongqing Pharscin Pharmacy Retail Chain Co., Ltd. and Chongqing Pharscin Biotech Co., Ltd.

Guided by the technology-led and innovation-driven principle, Pharscin Pharma stays committed to manufacturing high-quality products with special, sophisticated, unique, and novel features. At present, we have 68 drug varieties, including Chinese patent medicine, APIs, and finished pharmaceutical products. Among them, 49 drugs are in the catalog of National Medical Insurance, 46 drugs have domestic patents, and one has international patents.

Pharscin Pharma attaches great importance to scientific and technological innovation and has built a robust, innovative platform for the transformation of scientific and technical achievements. We have successfully applied the key technologies such as extraction of thermosensitive active ingredients of traditional Chinese Medicine, automatic transmission of powders, and production control of soft capsules into manufacturing. The company is now in the process of building an automated information management system, purposely realizing the informative,internet-based, digital, and intelligent management of production through the automated module control in every link of production.

Pharscin Pharma has built 11 domestically leading production lines for multiple dosage forms, including tablets, powders, granules, hard and soft capsules, powder for injection, freeze-dried powder for injection, small-volume injection, API syntheses, and botanical drug extraction, etc. Our manufactured products have a 100% passing rate in the finished product inspection, sampling inspection of the NMPA(former CFDA), national evaluation sampling inspection, and market sampling inspection.

Pharscin Pharma stays committed to academic promotion and has built a professional marketing team of more than 500 medical representatives to deliver advanced, accurate, and up-to-date information and services to medical workers. Our marketing network covers 31 provinces, cities, and autonomous regions, and is establishing its presence in overseas markets.